NCT04277442View on ClinicalTrials.gov

Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

March 11, 2020

Primary Completion Date

May 12, 2020

Study Completion Date

September 6, 2022

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Decitabine

Given IV

BIOLOGICAL

Nivolumab

Given IV

DRUG

Venetoclax

Given PO

Trial Locations (1)

43210

Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT04277442 - Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter